Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000687
UniProt IDQ92793
Primary gene name(s)CREBBP
Synonym gene name(s)CBP
Protein nameCREB-binding protein
Protein functionAcetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair, NER, PubMed:24939902. {ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:9707565}.
Subcellular locationCytoplasm. Nucleus. Note=Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q92793
Gene Ontology
(Biological Process)
Complete annatation
beta-catenin-TCF complex assembly [GO:1904837];
cellular lipid metabolic process [GO:0044255];
cellular response to UV [GO:0034644];
embryonic digit morphogenesis [GO:0042733];
histone acetylation [GO:0016573];
homeostatic process [GO:0042592];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
Notch signaling pathway [GO:0007219];
N-terminal peptidyl-lysine acetylation [GO:0018076];
positive regulation of transcription, DNA-templated [GO:0045893];
positive regulation of type I interferon production [GO:0032481];
protein acetylation [GO:0006473];
protein complex assembly [GO:0006461];
regulation of apoptotic process [GO:0042981];
regulation of cellular response to heat [GO:1900034];
regulation of smoothened signaling pathway [GO:0008589];
regulation of transcription, DNA-templated [GO:0006355];
regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418];
response to hypoxia [GO:0001666];
rhythmic process [GO:0048511];
signal transduction [GO:0007165];
stimulatory C-type lectin receptor signaling pathway [GO:0002223];
transcription initiation from RNA polymerase II promoter [GO:0006367];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
acetyltransferase activity [GO:0016407];
chromatin binding [GO:0003682];
core promoter proximal region sequence-specific DNA binding [GO:0000987];
damaged DNA binding [GO:0003684];
histone acetyltransferase activity [GO:0004402];
MRF binding [GO:0043426];
p53 binding [GO:0002039];
peptide N-acetyltransferase activity [GO:0034212];
RNA polymerase II activating transcription factor binding [GO:0001102];
RNA polymerase II transcription coactivator activity [GO:0001105];
RNA polymerase II transcription factor binding [GO:0001085];
signal transducer activity [GO:0004871];
transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001078];
transcriptional repressor activity, RNA polymerase II transcription factor binding [GO:0001191];
transcription coactivator activity [GO:0003713];
transcription factor activity, sequence-specific DNA binding [GO:0003700];
transcription factor binding [GO:0008134];
zinc ion binding [GO:0008270]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
histone acetyltransferase complex [GO:0000123];
nuclear body [GO:0016604];
nuclear chromatin [GO:0000790];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
transcription factor complex [GO:0005667]
Protein-protein interaction107777
Phylogenetic treeQ92793
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.649434705148570.04942334774568660.0989254577985376
AZA vs. DISU0.4473499469118620.07903541666732790.597337661502914
AZA vs. IL7-0.1313672081617770.4938749635779120.999311006273513
AZA vs. SAHA-0.7420411919757640.01041976283898080.100138746252095
DISU vs. CD31.084151587329950.003907455165681810.0132242880932841
DISU vs. IL7-0.5879523033218420.02028369872757010.178868612645241
DISU vs. SAHA-1.187302560637550.0001727697673180590.00578625147388994
DMSO vs. AZA0.07374889479732980.6592242914949561
DMSO vs. CD30.7114909523322850.02827886402005790.0598092217411444
DMSO vs. DISU-0.3754981368232740.1249794822383860.609140110135616
DMSO vs. IL7-0.1977071112153050.2707891094108590.76916667825006
DMSO vs. SAHA-0.8216259476127840.003334058375328630.0415897579809262
HIV vs. Mock in Activation0.4065808278558760.5341543647471070.999983755607037
HIV vs. Mock in Latency0.06693955339567960.684219946578210.999834320637052
IL7 vs. CD30.5242323348665730.1069570084646530.19962394608565
SAHA vs. CD3-0.1163079487208670.7774420957382910.840945476799888
SAHA vs. IL7-0.6139896589641750.02890342430727740.127357561534025
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.296469 0.0196926
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.911 1.163 1.031 1.092 0.99
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
202160_at 1.39 No downregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB08655 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1JSP NMR - B=1081-1197.
1LIQ NMR - A=376-402.
1RDT X-ray 2.4Å E=58-80.
1WO3 NMR - A=387-398.
1WO4 NMR - A=387-398.
1WO5 NMR - A=387-398.
1WO6 NMR - A=376-400.
1WO7 NMR - A=376-400.
1ZOQ X-ray 2.3Å C/D=2065-2111.
2D82 NMR - A=1081-1197.
2KJE NMR - A=1763-1854.
2KWF NMR - A=587-673.
2L84 NMR - A=1081-1197.
2L85 NMR - A=1081-1197.
2LXS NMR - A=587-673.
2LXT NMR - A=587-673.
2N1A NMR - B=1699-1751.
2RNY NMR - A=1081-1197.
3DWY X-ray 1.9Å A/B=1081-1197.
3P1C X-ray 1.8Å A/B=1081-1197.
3P1D X-ray 1.8Å A/B=1081-1197.
3P1E X-ray 1.8Å A/B=1081-1197.
3P1F X-ray 1.6Å A/B=1081-1197.
3SVH X-ray 1.8Å A/B=1081-1197.
4A9K X-ray 1.8Å A/B=1081-1197.
4N3W X-ray 1.9Å A=1080-1316.
4N4F X-ray 1.8Å A=1080-1316.
4NR4 X-ray 1.6Å A/B=1081-1197.
4NR5 X-ray 1.6Å A=1081-1197.
4NR6 X-ray 1.6Å A=1081-1197.
4NR7 X-ray 1.2Å A=1081-1197.
4NYV X-ray 1.8Å A/B/C/D=1081-1197.
4NYW X-ray 1.4Å A=1081-1197.
4NYX X-ray 1.1Å A=1081-1197.
4OUF X-ray 1.4Å A/B=1082-1197.
4TQN X-ray 1.7Å A=1081-1197.
4TS8 X-ray 2.0Å A=1081-1197.
4WHU X-ray 2.1Å A=1081-1197.
4YK0 X-ray 1.6Å A/B/C/D=1083-1196.
5CGP X-ray 1.9Å A=1081-1197.
5DBM X-ray 1.8Å A/B/C=1082-1197.
5I83 X-ray 1.3Å A=1082-1197.
5I86 X-ray 1.0Å A/B=1082-1197.
5I89 X-ray 1.0Å A=1082-1197.
5I8B X-ray 1.5Å A=1081-1312.
5I8G X-ray 1.4Å A=1081-1312.
5J0D X-ray 1.0Å A=1081-1197.
5JEM X-ray 2.5Å C/D/F/H=2065-2111.
5TB6 X-ray 1.7Å A=1081-1197.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
integrase interacts with 25011556
Tat recruits 9811832
Tat activates 16001085
Tat upregulates 16339753
Tat induces complex with 11160671
Tat interacts with 11080476
Tat regulates 11739381
Tat associates with 22073215
Tat inhibits 12154097
Tat acetylated by 10607594
Vpr binds 12208951
Tat binds 12549909
Tat regulated by 9733868

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)
hsa04068 FoxO signaling pathway - Homo sapiens (human)
hsa04110 Cell cycle - Homo sapiens (human)
hsa04310 Wnt signaling pathway - Homo sapiens (human)
hsa04330 Notch signaling pathway - Homo sapiens (human)
hsa04350 TGF-beta signaling pathway - Homo sapiens (human)
hsa04520 Adherens junction - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04720 Long-term potentiation - Homo sapiens (human)
hsa04916 Melanogenesis - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa04922 Glucagon signaling pathway - Homo sapiens (human)
hsa05016 Huntington's disease - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05206 MicroRNAs in cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)